Health ❯ Healthcare ❯ Research ❯ Meta-Analysis

Efficacy Studies

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

Umbrella Review Finds No Strong Evidence for Alternative Autism Interventions